Bolder Surgical
2022
$160M
Outcome
Enhanced procedural offerings for minimally invasive gynecologic surgeries alongside MyoSure and NovaSure.
Hologic, Inc.
Medical TechnologyFounded 1985- HQ today: Marlborough, Massachusetts
Reviewed by Swet Parvadiya
Company data updated: November 2026
Acquisitions
Hologic Acquisitions
4
Major Deals Covered
$10.9B
Disclosed Deal Value
What are Hologic's biggest acquisitions?
Hologic's largest disclosed acquisition here is Cytyc Corporation for $6.2B in 2007. This page covers 4 major deals from 2007 to 2022, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- Cytyc Corporation ($6.2B)
- First deal
- 2007
- Most recent
- 2022
| Company | Year | Price | Purpose |
|---|---|---|---|
| Cytyc Corporation | 2007 | Undisclosed | — |
| Gen-Probe Incorporated | 2012 | Undisclosed | — |
| Mobidiag Oy | 2021 | Undisclosed | — |
| Bolder Surgical | 2022 | Undisclosed | — |
- What companies has Hologic bought?
- Major acquisitions by Hologic documented here include Cytyc Corporation (2007), Gen-Probe Incorporated (2012), Mobidiag Oy (2021) and Bolder Surgical (2022).
- What is Hologic's most recent acquisition?
- The most recent Hologic acquisition documented here is Bolder Surgical, in 2022, for $160M.
Mobidiag Oy
2021
$795M
Outcome
Integrated Novodiag platform to complement high-throughput Panther systems with rapid, near-patient molecular testing.
Gen-Probe Incorporated
2012
$3.7B
Outcome
Created a high-margin recurring consumable revenue engine that anchors Hologic's diagnostics division today.
Cytyc Corporation
2007
$6.2B
Outcome
Massively expanded revenue scale and established dominant commercial relationships with OB/GYNs worldwide.
Hologic, Inc.'s Growth & Acquisition Strategy
Hologic's multi-year growth strategy encompasses expanding the global installed base of Panther and Genius 3D systems, accelerating consumable assay pull-through, launching next-generation digital health and AI-assisted diagnostic tools, and pursuing disciplined bolt-on acquisitions that strengthen its core clinical pillars.
How Hologic, Inc. Makes Money
Hologic operates a high-margin, razor-and-blade business model anchored by proprietary capital equipment placements (such as Panther and Dimensions mammography systems) that drive predictable, recurring consumable revenues through high-throughput molecular assays, biopsy needles, and surgical disposables. This synergistic model ensures robust customer stickiness, high switching costs, and strong operating profitability.
Hologic Acquisitions FAQ
What was Hologic's largest and most transformative acquisition?
Hologic's largest transaction was the 2007 acquisition of Cytyc Corporation for $6.2 billion, which secured the ThinPrep Pap test and NovaSure endometrial ablation, instantly establishing Hologic as a women's health leader.
Why was the acquisition of Gen-Probe so critical for Hologic?
The 2012 acquisition of Gen-Probe for $3.7 billion brought the Panther molecular diagnostics instrument and Aptima assay menu into Hologic, creating a highly profitable recurring consumable revenue engine.
What recent acquisitions has Hologic completed to expand its portfolio?
Recent strategic acquisitions include Mobidiag Oy in 2021 for ~$800 million (expanding point-of-care molecular testing) and Bolder Surgical in 2022 (adding advanced laparoscopic vessel-sealing instruments).
What is Hologic's overarching M&A philosophy?
Hologic pursues a disciplined M&A strategy focused on acquiring proprietary, patent-protected medtech platforms that address major unmet clinical needs and offer clear pathways for global commercial acceleration.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Hologic
Core profile pages, founders and related research hubs for this company.